Pharmaceuticals

Primary Biliary Cholangitis Therapeutics Market 2026–2035 advancing with rare disease focus

March 24, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Primary Biliary Cholangitis Therapeutics Market Between 2026 And 2030?

The primary biliary cholangitis therapeutics market size has experienced swift expansion recently. It is projected to increase from $1.01 billion in 2025 to $1.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.9%. This historical growth can be attributed to several factors including limited treatment options for PBC, the rising prevalence of autoimmune liver diseases, more widespread liver disease awareness campaigns, a reliance on ursodeoxycholic acid monotherapy, and the development of hospital infrastructure for liver disease care.

The primary biliary cholangitis therapeutics market size is projected to experience substantial expansion in the coming years. It is anticipated to reach $1.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.9%. This expansion during the forecast period is propelled by advancements in obeticholic acid and combination therapies, an increase in investigational drugs and pipeline candidates, the growing uptake of receptor agonists and modulators, heightened patient awareness coupled with early diagnosis efforts, and the broadening of online and retail pharmacy distribution channels. Key trends anticipated for this period encompass the increasing utilization of ursodeoxycholic acid and obeticholic acid treatments, the rise of combination therapies and pipeline drugs, a greater emphasis on prompt diagnosis and continuous disease monitoring, the expansion of hospital and retail pharmacy distribution channels, and an enhanced understanding of autoimmune liver diseases along with patient education.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25887&type=smp

What Drivers Are Influencing The Primary Biliary Cholangitis Therapeutics Market?

The primary biliary cholangitis therapeutics market is expected to expand due to the rising prevalence of liver diseases. Liver diseases refer to a variety of conditions that hinder the normal functioning of the liver, frequently resulting in inflammation, scarring, or liver failure. The increasing occurrence of liver diseases is linked to a rise in alcohol consumption, as excessive intake damages liver cells, leading to inflammation and chronic liver conditions. Primary biliary cholangitis therapeutics assist in managing liver diseases by addressing bile duct inflammation, slowing disease progression, and preserving liver function. These treatments improve patient outcomes by reducing symptoms, enhancing quality of life, and delaying the need for liver transplantation. For instance, in September 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal public health agency, chronic liver disease and cirrhosis were responsible for 52,222 deaths in the United States in 2023, positioning it as the ninth leading cause of death. Consequently, the increasing prevalence of liver diseases is driving the growth of the primary biliary cholangitis therapeutics market.

Which Market Segments Are Examined In The Primary Biliary Cholangitis Therapeutics Market Study?

The primary biliary cholangitis therapeutics market covered in this report is segmented –

1) By Drug: Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs

2) By Mechanism Of Action (MOA): Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action

3) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies

4) By Use: Human, Veterinary

Subsegments:

1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid, Generic Ursodeoxycholic Acid, Combination Therapies With Ursodeoxycholic Acid

2) By Obeticholic Acid: Monotherapy, Combination Therapy, Branded Obeticholic Acid

3) By Other Drugs: Fibrates, Budesonide, Immunosuppressants, Investigational Drugs Or Pipeline Candidates

Which Trends Are Influencing The Primary Biliary Cholangitis Therapeutics Market?

Major companies within the primary biliary cholangitis therapeutics market are concentrating on developing advanced products and securing approvals, particularly for peroxisome proliferator-activated receptor agonists, to enhance bile acid metabolism and decelerate disease progression in patients. Peroxisome proliferator-activated receptor (PPAR) agonists are medications that activate PPAR proteins, which are instrumental in regulating genes linked to metabolism, inflammation, and energy balance. For instance, in August 2024, Gilead Sciences Inc., a US-based pharmaceutical company, was granted accelerated approval from the U.S. Food and Drug Administration (FDA) for Livdelzi (seladelpar). This approval is for the treatment of primary biliary cholangitis (PBC) in adults who have demonstrated an insufficient response to ursodeoxycholic acid (UDCA) or cannot tolerate UDCA. Livdelzi is an oral, selective PPARd agonist that operates by activating the PPARd receptor to modulate genes involved in reducing liver inflammation, improving bile acid metabolism, and consequently slowing the progression of primary biliary cholangitis (PBC).

Who Are The Primary Competitors In The Primary Biliary Cholangitis Therapeutics Market?

Major companies operating in the primary biliary cholangitis therapeutics market are Novartis AG, Gilead Sciences Inc., Ipsen Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics

Read the full primary biliary cholangitis therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-therapeutics-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Primary Biliary Cholangitis Therapeutics Market?

North America was the largest region in the primary biliary cholangitis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Primary Biliary Cholangitis Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25887&type=smp

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Therapeutics Market 2026, By The Business Research Company

Primary Biliary Cholangitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Liver Diseases Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795